ClinicalTrials.gg
RecruitingNCT06056271COMPANION AIUpdated Dec 10, 2025

Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation

An observational study in Atrial Fibrillation, sponsored by Volta Medical. Recruiting at 4 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Volta Medical · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Planned enrollment
109th of 308
400 · median 200
Started
2024
with 53 others
Observational
308 of 993
58 open now
Primary completion
2027-12
later than 137 of 219 live
Registered
849th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 109th largest by planned enrollment of the 308 observational ones that give a count, is one of 54 that started in 2024, is one of 308 observational ones, reaches primary completion later than 137 of the 219 other live ones, and was the 849th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Xplorer systems during AF ablation procedures.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients indicated for ablation for atrial fibrillation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 21 years of age or older who is:

    • indicated for AF ablation or
    • Who has received an AF-ablation with the past 24 months where VX1 was used or
  2. Patients are receiving or received a catheter ablation procedure for AF according to current guidelines
  3. Patients must be able and willing to provide written to participate in the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Patients not indicated or were not indicated for catheter ablation according to current guidelines
  2. Patients with AF secondary to an obvious reversible cause
  3. Patients who are or may potentially be pregnant
  4. Enrollment in an study evaluating another non-VX1 investigational device, biologic, or drug
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Interventions

  • DeviceAF Ablation

    Percutaneous, catheter-based ablation of atrial fibrillation

06

What researchers measure

Primary outcomes

  1. Primary Clinical Efficacy Outcome

    Percentage of subjects free from clinically significant AF or atrial arrhythmia recurrences, after one or multiple ablation procedures, stratified by type of clinical workflow and ablation history.

    Time frame: 12 and 24 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 45 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2023
First posted
Sep 28, 2023
StartActual
Mar 19, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06056271
Lead sponsor
Volta Medical
Collaborators
Heart Rhythm Clinical and Research Solutions, LLC
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Mar 19, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 10, 2025

Study contacts

Daniel Guerrero
Contact
daniel.guerrero@volta-medical.com
612-227-1483

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion